T Cell Transcriptomic Profiling for Parkinson's Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating Parkinson's Disease (PD) are limited, with a need for efficient detection of cell signatures and effective therapeutic interventions to address the complex and progressive nature of the neurodegenerative disorder.
Innovation Solution
The use of specific gene signatures associated with T cell subsets, including those involved in oxidative stress, autophagy, and inflammation, to develop diagnostic methods and therapeutic targets for PD, involving the detection of genes such as CX3CR1, CCR5, and LRRK2, and the administration of treatments like immunotherapy and adoptive cell therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for Parkinson's Disease, then the diagnosis can be made, but the detection precision and early intervention capability are insufficient
Solution Approach 1:
The patent segments the diagnostic approach by focusing on specific T cell subsets (CD4+ and CD8+ memory T cells) and their distinct transcriptomic profiles rather than examining all immune cells uniformly. This segmentation enables more precise detection of PD-specific immune responses while reducing background noise from non-relevant cell types.
Solution Approach 2:
The patent uses transcriptomic signatures and gene expression profiles as intermediary markers that mediate between the immune system's complex responses and the diagnostic detection process. These molecular intermediaries provide a measurable link to PD pathogenesis that is more sensitive than current clinical diagnostic methods.
2Reliability
If comprehensive treatment options are explored for PD, then therapeutic effectiveness may improve, but the complexity of treatment protocols increases
Solution Approach 1:
The patent applies local quality by targeting specific T cell subsets (CD4+ and CD8+ memory T cells) with distinct transcriptomic profiles rather than applying uniform treatments to all immune cells. This localized approach allows for tailored immunotherapies that address specific pathological mechanisms in different patient subsets, improving therapeutic effectiveness while maintaining manageable protocol complexity.
Solution Approach 2:
The patent utilizes parameter changes in gene expression levels (such as CX3CR1, CCR5, CCR1, LRRK2, LAMP3, and aquaporin) to identify and stratify patients for different therapeutic interventions. By monitoring these molecular parameters, the complex immune response to PD can be translated into discrete, actionable treatment decisions.
3Measurement precision
If T cell transcriptomic profiling is performed to identify PD signatures, then diagnostic accuracy improves, but the complexity of analysis and detection methods increases
Solution Approach 1:
The patent extracts and focuses on specific transcriptomic signatures and gene expression profiles from the complex immune system. By isolating and measuring key genes (CX3CR1, CCR5, CCR1, LRRK2, LAMP3, aquaporin) and their products, the method simplifies the detection process while maintaining high diagnostic accuracy through targeted molecular assays rather than comprehensive genomic sequencing.
Data Source
AI summary
This disclosure provides methods for determining whether a subject is suffering from a neurodegenerative disease, and/or methods of treating a neurodegenerative disease. The disclosed methods comprise detecting differential expression one or more genes or gene products from a sample obtained from the subject.